CompletedNCT05053503
Ear-based nerve stimulation alongside naltrexone for opioid relapse prevention
About this title
Read the official source — NCT05053503Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Rancho Mirage and 3 more locationsSee all locations and recruitment
Study information
Study start dateStarted: May 27, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 108
- Sponsor
- Spark Biomedical, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Device, Drug
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05053503
- Official title
Show the full official title
Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Rancho Mirage · Crownsville · Center City
1 more locations
- Plymouth
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Spark Biomedical, Inc.
Did this study involve medication?
Yes. The study involved medication, including Lofexidine and Extended-release injectable naltrexone.
Who was this study for?
Listed age limits: 18 years to 65 years.
